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Abstract
Elevated plasma concentrations of the uremic toxin asymmetrical dimethylarginine (ADMA)
and low plasma concentrations of L-homoarginine are independently associated with car-
diovascular events and total mortality. Enzymes degrading ADMA [dimethylaminohydrolase
1 (DDAH1)] and synthesizing L-homoarginine [L-arginine:glycine amidinotransferase
(AGAT)] are expressed in human proximal tubule cells. So far, it is not known which trans-
port protein in the basolateral membrane of proximal tubule cells is mediating the uptake of
ADMA into the cells for subsequent degradation or the export of intracellularly synthesized
L-homoarginine. One study suggested that the uptake transporter OATP4C1 (gene symbol
SLCO4C1) may be involved in the transport of ADMA and other uremic toxins. OATP4C1 is
a member of the SLCO/SLC21 family of solute carriers, localized in the basolateral mem-
brane of human proximal tubule cells. By using stably-transfected HEK cells overexpressing
human OATP4C1, we demonstrate that ADMA and L-homoarginine are substrates of
OATP4C1 with Km values of 232.1 μM and 49.9 μM, respectively. ADMA and the structurally
related uremic toxin SDMA (100 μM) inhibited OATP4C1-mediated L-homoarginine uptake
(P < 0.01), whereas other tested uremic toxins such as urea and p-cresyl sulfate have no
effect on OATP4C1-mediated transport. Preloading experiments (300 μM for 60 min) with
subsequent efflux studies revealed that OATP4C1 also facilitates efflux e.g. of L-homoargi-
nine. Both ADMA and L-homoarginine are substrates of human OATP4C1. Because proxi-
mal tubule cells are one site of ADMA metabolism and L-homoarginine synthesis, we
postulate a protective role of OATP4C1 by mediating uptake of ADMA from and export of L-
homoarginine into the systemic circulation.
Introduction
L-homoarginine is an endogenous, non-proteinogenic amino acid, which may increase nitric
oxide availability and enhance endothelial function [1]. In recent years, low urinary and
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circulation L-homoarginine concentrations emerged as a risk marker for renal and cardiovas-
cular diseases and mortality [2,3]. L-homoarginine is endogenously formed from lysine and
occurs in various body fluids and organs [4]. As demonstrated by Genome Wide Association
studies (GWAS studies), one single-nucleotid polymorphism (SNP) in the gene encoding for
the L-arginine:glycine amidinotransferase (AGAT) is associated with circulating L-homoargi-
nine concentrations [5,6], indicating that AGAT is one major enzyme for endogenous L-
homoarginine synthesis. The kidney is one important site of AGAT expression [7] and L-
homoarginine plasma concentration is closely linked to glomerular filtration rate. Lower L-
homoarginine concentrations were found in patients with impaired kidney function [8], sug-
gesting that less L-homoarginine is synthesized in proximal tubule cells and exported into
plasma in patients with reduced kidney function thereby indicating an important role of the
kidney in L-homoarginine metabolism and homeostasis [2].
While lower L-homoarginine concentrations are independently associated with cardiovas-
cular and all-cause mortality, high plasma concentrations of the structurally related arginine
derivative and uremic toxin asymmetric dimethylarginine (ADMA) could be detected in CKD
(chronic kidney disease) patients [9]. Since then, numerous studies have linked elevated
ADMA plasma concentrations to cardiovascular events and total mortality [10]. ADMA is
considered an important uremic toxin and its plasma concentration increases up to three-fold
in advanced CKD [11]. Interestingly, the kidney is not only involved in the filtration but also
in the metabolism of ADMA by dimethylaminohydrolase 1 (DDAH1) and alanine:glyoxylate
aminotransferase 2 [AGXT2 [12]]. DDAH1 is expressed in human renal proximal tubule cells
and likely responsible for the degradation of ADMA after it is taken up from blood into proxi-
mal tubule cells.
The uptake transporter OATP4C1 (gene symbol SLCO4C1) is the only member of the
SLC21/SLCO family of transport proteins (SLC = solute carrier). An immunohistochemical
analysis of kidney biopsies obtained from transgenic rats expressing human OATP4C1
showed, that OATP4C1 is located in the basolateral membrane of the proximal tubule epithe-
lium of the S2 segment.
Using this transgenic rat model, an involvement of this transporter in the elimination of
uremic toxins was studied [13]. The authors found, that the overexpression of human
OATP4C1 in rat kidney reduced hypertension, inflammation and cardiomegaly after five-
sixths nephrectomy, an established model of renal failure. Furthermore, this overexpression
decreased the plasma concentrations of the uremic toxins ADMA, guanidine succinate, and
trans-aconitate suggesting that several uremic toxins might be substrates of this transport pro-
tein. Finally, the authors concluded that the upregulation of OATP4C1 in patients with CKD
might have a therapeutic potential by facilitating the renal excretion of uremic toxins that are
substrates of this transporter [13].
Based on these findings and because OATP4C1-mediated transport of ADMA or L-homo-
arginine has not been studied so far, we established HEK cells stably overexpressing human
OATP4C1. Using labeled ADMA and L-homoarginine as well as L-arginine, we investigated
OATP4C1-mediated transport of these substances to gain more insights into the role of this
transport protein for the homeostasis of ADMA and L-homoarginine, which are both acting
antagonistically in the cardiovascular system.
Materials and methods
Materials
[3H]labeled ADMA (25 Ci/mmol) was from BIOTREND Chemikalien GmbH (Cologne, Ger-
many), [3H]labeled L-arginine (43 Ci/mmol) and [3H]labeled digoxin (20 Ci/mmol) was
OATP4C1-mediated transport of ADMA and L-homoarginine
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purchased from American Radiolabeled Chemicals, Inc. (St. Louis, U.S.A.). [3H]labeled L-
homoarginine (6 Ci/mmol) was from ViTrax (St. Jefferson, U.S.A.). Unlabeled ADMA, SDMA
and L-arginine were from Enzo Life Sciences GmbH (Lo¨rrach, Germany) and unlabeled L-
homoarginine was obtained from Acros Organics (New Jersey, U.S.A.). Urea was purchased
from Carl Roth GmbH & Co. KG (Karlsruhe, Germany), sodium butyrate was obtained from
Merck KGaA (Darmstadt, Germany) and p-cresyl sulfate was provided by Prof. Dr. Roos
Masereeuw from the Utrecht Institute for Pharmaceutical Sciences (Utrecht, The Nether-
lands). Dulbecco‘s phosphate buffered saline, fetal bovine serum, geneticin-disulfate (G418),
minimum essential medium, penicillin streptomycin solution and 0.05%-trypsin-EDTA
(0.02%) solution were from Life Technologies GmbH (Darmstadt, Germany). All other sub-
stances were purchased from Sigma-Aldrich (St. Louis, USA) with the highest grade available.
12-well cell culture plates were from Greiner Bio-One (Frickenhausen, Germany). BCA Pierce
Protein Assay Kit was obtained from Life Technologies GmbH.
Antibodies
The polyclonal rabbit anti-human OATP4C1 antiserum AVV was directed against the carbox-
yterminal end of the OATP4C1 protein and was obtained from the Division of Tumor Bio-
chemistry of the German Cancer Research Center (Heidelberg, Germany).
Cell culture
HEK293 cells were cultured in minimal essential medium, which was supplemented with 10%
heat-inactivated fetal bovine serum, 100 U/ml penicillin, and 100 μg/ml streptomycin. G418
(800 μg/ml) was used as selection antibiotic. Cells were incubated at 37˚C and 5% CO2. The
cells were routinely subcultured using trypsin 0.05%-EDTA (0.02%) solution.
Generation of a HEK293 cell line stably overexpressing human OATP4C1
Cloning of the SLCO4C1 cDNA encoding human OATP4C1 was performed using an RT-PCR
approach with the primers oOATP4C1-RT.for (5`-CTCCTATAACTGTGTCTATCC-3`) and
oOATP4C1-RT.rev (5`-CCCATTTCACCCTTCTTTTACT-3`). The obtained cDNA was
cloned into the expression plasmid pcDNA3.1(+), sequenced and base pair exchanges leading
to amino acid exchanges, compared to the reference sequence (accession number NM_1809
91.4) were corrected using the QuikChange Lightning Multi-site-directed mutagenesis kit
(Agilent technologies, La Jolla, USA). The resulting plasmid pOATP4C1.31 contains the
SLCO4C1 cDNA encoding a human OATP4C1 protein 100% identical to the one encoded by
the reference sequence. HEK293 cells were transfected with the EffecteneTM Transfection
Reagent Kit (QIAGEN GmbH, Hilden, Germany) according to the manufacturer‘s instruc-
tions. After selection with G418 (800 μg/ml) for 4 weeks, transfected HEK cells were screened
for SLCO4C1 mRNA expression using LightCycler-based quantitative RT-PCR as described
[14]. These cells were used in control experiments to exclude cell specific effects.
Immunofluorescence microscopy
Localization of the OATP4C1 protein was analyzed by confocal laser scanning microscopy
and performed with an Axiovert 100 M microscope (Carl Zeiss GmbH, Jena, Germany) and
the Zeiss LSM Image Browser version 4.2.0.121. HEK-OATP4C1 and HEK-VC cells were
grown on poly-D-lysine coated object slides in cell culture plates at an initial cell density of 5 x
106 cells/slide. After 24 h of incubation at 37˚C, the cells were induced with 10 mM sodium
butyrate [15]. Object slides were incubated with polyclonal rabbit anti-human OATP4C1
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antiserum AVV (1:500 in H2O containing 2% bovine serum albumin) over night. Slides were
subsequently incubated with a Cy3-conjugated goat anti-rabbit IgG FC secondary antibody
(1:500 in H2O only, Dianova GmbH, Hamburg, Germany). The nuclei were counterstained
with DAPI (100 ng/ml solution in H2O, AppliChem GmbH, Darmstadt, Germany).
Immunoblot analysis
Immunoblot analysis was conducted as described before [14]. Human kidney tissue was used
as positive control. Protein content of the obtained samples and the positive control was deter-
mined by using the BCA Assay according to the manufacturer‘s instructions. After electroblot-
ting, the membrane was incubated in 1:1 000 diluted polyclonal rabbit anti-human OATP4C1
AVV antiserum. Goat anti-rabbit IgG (1:10 000), conjugated with horseradish peroxidase (GE
Healthcare Life Sciences, Buckinghamshire, UK), was used as secondary antibody. To detect
β-actin, the membrane was incubated in stripping buffer (Thermo Scientific, Rockford, USA)
and incubated in a 1:10 000 diluted monoclonal mouse anti-human β-actin primary antibody
(Sigma-Aldrich, St. Louis, USA). Horseradish peroxidase-labeled goat anti-mouse IgG (Dia-
nova GmbH, Hamburg, Germany) was used as secondary antibody in a dilution of 1:2 000.
For protein detection, ClarityTM ECL Western Blotting Substrate (Bio-Rad Laboratories Inc.,
Hercules, USA) was used. Digital quantification was conducted with ChemiDoc XRS detection
system (Bio-Rad Laboratories GmbH).
Transport assays & inhibition studies
HEK-OATP4C1 and HEK-VC cells were seeded into poly-D-lysine coated 12-well plates with
an initial density between 5 x 105 cells/well and 7 x 105 cells/well, incubated for 24 h at 37˚C
and 5% CO2 and subsequently induced with 10 mM sodium butyrate [15]. Transport assays
were performed as described earlier [16,17]. The measured substrate concentration in the lysat
was normalized to the protein content, which was determined using BCA Assay.
During characterization of stably-transfected cells, digoxin was used in a concentration of
5 μM. Initial transport experiments using ADMA, L-arginine and L-homoarginine as potential
substrates of OATP4C1 were performed with low (1 μM) and high (50 μM) substrate concen-
trations. Time dependency experiments were performed with incubation periods of 1, 2, 5 and
10 minutes. For the determination of the kinetic parameters, substrates were applied in con-
centrations between 1 μM and 500 μM with an incubation time of 2 minutes. To measure
the potential influence of uremic toxins or of digoxin on the OATP4C1-mediated uptake,
L-homoarginine was used as substrate (20 μM) and the tested uremic toxins were simulta-
neously applied in a concentration of 50 μM. Digoxin was used in a concentration of 5 μM.
In additional studies the dose-dependent inhibitory effect of ADMA and SDMA on the
OATP4C1-mediated uptake of physiological L-homoarginine concentrations was examined.
Here cells were incubated with 2 μM of L-homoarginine and increasing concentrations of
either ADMA or SDMA between 0.5 μM and 1000 μM. Based on these data IC50 values were
calculated.
Efflux transport assay
The OATP4C1-mediated efflux of ADMA, L-arginine and L-homoarginine was studied by
preloading the cells with 300 μM of the compounds for 60 minutes. Cells were then washed
with 1 ml of fresh prewarmed uptake buffer (37˚C). Immediately after washing the cells, 800 μl
of prewarmed uptake buffer were applied onto the cells for incubation periods of 2, 5 and 10
minutes. The transport activity was stopped by putting the cells on ice. The supernatant was
collected and the cells were washed three times with cold uptake buffer and lysed. The
OATP4C1-mediated transport of ADMA and L-homoarginine
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Fig 1. Characterization of HEK293 cells stably expressing the human renal transport protein OATP4C1 (gene symbol SLCO4C1). (A) Analysis of
SLCO4C1 (encoding human OATP4C1) mRNA expression. The expression is quantified relative to the expression of the housekeeping gene β-actin.
HEK-VC = cell line transfected with the empty vector and selected under the same conditions serving as control cell line, HEK-OATP4C1 = cell line
recombinantly overexpressing human OATP4C1. Data are expressed as means ± SEM. The experiment has been performed once with n = 3. ���P< 0.001.
(B) Immunoblot analysis of OATP4C1 expression in the control cell line (HEK-VC), the cell line expressing human OATP4C1 (HEK-OATP4C1) and in a
OATP4C1-mediated transport of ADMA and L-homoarginine
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radioactivity was measured in the lysate and in the supernatant by liquid scintillation counting.
To verify that the observed efflux was caused by transporter activity and not by passive diffu-
sion, the efflux of L-homoarginine was also investigated at an incubation temperature of 4˚C.
Statistical analysis
All data were expressed as means ± SEM. Unless stated otherwise, an unpaired, two-tailed t-
test was conducted to analyze the statistical significance in the differences of cellular accumula-
tion, mRNA expression and protein expression. Statistical significance was considered to be
given at p-value < 0.05. Net uptake was calculated by subtracting the accumulation of the
respective compound into the HEK-VC cell line from the accumulation into the HEK-
OATP4C1 cell line. The percentagewise inhibition of OATP4C1-mediated transport caused
by uremic toxins was calculated by comparing the inhibited transport to a control experiment,
which was conducted in the absence of the respective inhibitor.
Km and IC50 values were calculated by using GraphPad Prism (Version 5.01, 2007, Graph-
Pad Software, San Diego, CA, USA).
The efflux data for every time point were calculated in relation to the original substrate con-
tent after preloading. This calculation has been done individually for the HEK-OATP4C1 cells
and the respective control cell line.
The percentagewise content of the applied compound in the HEK-OATP4C1 and HEK-VC
cells was plotted against the incubation time.
The amount of compound in the supernatant was analogously expressed for every time
point in relation to the original content of the compound in the lysate.
Results
HEK293 cells recombinantly overexpressing human OATP4C1
We first established HEK293 cells stably overexpressing human OATP4C1. After stable trans-
fection and clone selection, the cell clone with the highest SLCO4C1 mRNA (encoding
OATP4C1) expression showed 213 ± 19% SLCO4C1 mRNA expression relative to the expres-
sion of the housekeeping gene β-actin (Fig 1A). Immunoblot analysis demonstrated that this
clone showed a strong overexpression of the OATP4C1 protein with a molecular mass in the
same range as the endogenously synthesized OATP4C1 protein in human kidney samples (Fig
1B). The localization of the recombinantly expressed protein was analyzed by confocal laser
scanning microscopy demonstrating a distinct membrane staining compared to the unspecific
staining of the HEK-VC cells (Fig 1C).
In uptake experiments, we observed a significantly higher accumulation of ADMA, L-argi-
nine and L-homoarginine in HEK-OATP4C1 cells compared to HEK-VC cells at a low sub-
strate concentration of 1 μM (Fig 2A, 2C and 2E), which is in the physiological range for
ADMA and L-homoarginine and at a high concentration of 50 μM (Fig 2B, 2D and 2F).
OATP4C1-mediated uptake of ADMA, L-arginine and L-homoarginine
Next, we investigated the time dependency of the OATP4C1-mediated uptake using a sub-
strate concentration of 25 μM at incubation time points of 1, 2, 5 and 10 minutes. These uptake
experiments demonstrated linearity of net uptake for ADMA and L-homoarginine (Fig 3A
and 3C) up to two minutes and for L-arginine (Fig 3B) up to five minutes. Therefore,
human kidney sample. (C) Confocal laser scanning microscopy analyzing the localization of OATP4C1 in the control cell line (HEK-VC) and in the
transfectant (HEK-OATP4C1).
https://doi.org/10.1371/journal.pone.0213747.g001
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concentration dependency and inhibition experiments were conducted with an incubation
time of two minutes.
To determine kinetic parameters, concentration dependency studies were performed
using substrate concentrations between 1 μM and 500 μM. For ADMA a Km value of
232.1 ± 78.9 μM, for L-arginine a Km value of 48.1 ± 5.7 μM and for L-homoarginine a Km
value of 49.9 ± 9.6 μM was calculated (Fig 4).
Inhibition of OATP4C1-mediated L-homoarginine uptake by uremic
toxins
Next, we investigated if the OATP4C1-mediated net uptake of L-homoarginine (2 μM) could
be inhibited by ADMA and the related uremic toxin SDMA. Both substances were applied in
concentrations between 0.5 and 1000 μM and IC50 values were determined (Fig 5A and 5B).
ADMA and SDMA inhibited OATP4C1-mediated L-homoarginine uptake in a concentra-
tion-dependent manner with IC50 values of 117 ± 1.3 μM and 54 ± 1.3 μM for ADMA and
SDMA, respectively. Significant inhibition was observed at a concentration of 50 μM ADMA
and SDMA but even at lower ADMA and SDMA concentrations inhibition of OATP4C1-me-
diated L-homoarginine uptake could be detected.
Several other uremic toxins such as kynurenine and indoxyl sulfate showed no significant
modulation of OATP4C1-mediated L-homoarginine net uptake (Fig 6A–6H) at the tested
concentration of 50 μM.
OATP4C1-mediated efflux of ADMA and L-homoarginine
Using the published OATP4C1 substrate digoxin for uptake experiments, we detected a signif-
icantly reduced intracellular accumulation of digoxin in HEK-OATP4C1 cells in comparison
to the uptake into HEK-VC cells under standardized uptake conditions (P < 0.001; S1A Fig).
This difference was abolished by the (non-selective) inhibitor cyclosporine A (S1B Fig). These
findings point to an OATP4C1-mediated efflux of digoxin. To study possible OATP4C1-me-
diated efflux with respect to the arginine derivatives, preloading experiments were performed.
After preloading the cells with 300 μM of the respective substrate, the remaining intracellular
radioactivity in the lysate (Fig 7A) and the appearance of radioactivity in the supernatant (Fig
7B) was measured immediately after preloading and after 2, 5 and 10 minutes. For ADMA and
L-homoarginine these preloading experiments demonstrated a highly significant reduction in
radioactivity in the lysate of HEK-OATP4C1 cells compared to HEK-VC cells, accompanied
by a significant increase in radioactivity in the respective supernatant (Fig 7A and 7B). For L-
arginine this significant increase in the supernatant could also be detected (Fig 7B), but only a
slight and not significant intracellular decrease was measured (Fig 7A).
To test, if this export from HEK-OATP4C1 and HEK-VC cells was a transporter-mediated
process, experiments were repeated with L-homoarginine as substrate at 4 ºC and 37 ºC. As
expected, at 37 ºC a significant increase in radioactivity in the supernatant of the HEK-
OATP4C1 cells could be detected after 2, 5 and 10 minutes compared to HEK-VC cells (Fig
8B). At the same temperature, the amount of radioactivity was reduced in the lysate (Fig 8A)
of the HEK-OATP4C1 cells (significant reduction after 10 minutes). At 4 ºC, no significant dif-
ferences between HEK-OATP4C1 and HEK-VC cells could be detected at the examined time
Fig 2. Uptake experiments using 1 μM (A, C, E) and 50 μM (B, D, F) of the respective substance. Black bars represent
the uptake into the OATP4C1-expressing cell line (HEK-OATP4C1) and white bars represent the uptake into the control
cell line (HEK-VC). Data are expressed as means ± SEM. Studies were performed in two experiments with n = 2 (n = 4).
��P< 0.01; ���P< 0.001.
https://doi.org/10.1371/journal.pone.0213747.g002
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Fig 3. Time dependency experiments for OATP4C1-mediated ADMA (A), L-arginine (B) and L-homoarginine
(C) net uptake obtained from experiments with HEK-OATP4C1 and HEK-VC cells. Shown are the net uptake
values obtained at 1, 2, 5 and 10 minutes of incubation. Data are expressed as means ± SEM. Experiments were
performed on two separate days with n = 3 each (n = 6).
https://doi.org/10.1371/journal.pone.0213747.g003
OATP4C1-mediated transport of ADMA and L-homoarginine
PLOS ONE | https://doi.org/10.1371/journal.pone.0213747 March 13, 2019 9 / 19
OATP4C1-mediated transport of ADMA and L-homoarginine
PLOS ONE | https://doi.org/10.1371/journal.pone.0213747 March 13, 2019 10 / 19
points. However, highly significant differences could be measured in the supernatant after
2, 5 and 10 minutes (Fig 8B) and in the lysate after 5 and 10 minutes (Fig 8A) comparing
HEK-OATP4C1 cells incubated at 4 ºC and 37 ºC demonstrating that this L-homoarginine
efflux is transporter-mediated.
Discussion
Toyohara and coworkers [13] showed in a landmark study that the transport protein
OATP4C1 could be involved in the renal secretion of selected uremic toxins. It was therefore
the aim of our study to investigate the role of OATP4C1 for the transport of the uremic toxin
ADMA and the structurally related substances L-homoarginine and L-arginine. We estab-
lished stably-transfected HEK cells recombinantly overexpressing the human OATP4C1 pro-
tein 100% identical to the protein encoded by the reference sequence (NM_180991.4). Since
overexpression of human OATP4C1 in transgenic rats decreased plasma concentrations of the
uremic toxin ADMA [13], we first tested OATP4C1-mediated uptake of the uremic toxin
ADMA, of L-arginine and of the cardioprotective biomarker L-homoarginine. All three sub-
stances could be identified as substrates of human OATP4C1 (Figs 2 and 4). Furthermore,
ADMA and the closely related uremic toxin SDMA inhibited OATP4C1-mediated L-homoar-
ginine uptake in a dose-dependent manner (Fig 5) with IC50 values of 116 μM and 54 μM,
respectively, whereas other known uremic toxins had no effect on OATP4C1-mediated L-
homoarginine uptake (Fig 6). L-homoarginine can also be exported by OATP4C1 out of cells
as demonstrated by preloading experiments (Figs 7 and 8).
As already indicated above, several studies have demonstrated that high ADMA plasma
concentrations are associated with all-cause mortality and incident cardiovascular events [10],
whereas on the other hand low L-homoarginine plasma concentrations have been identified as
an independent risk marker for renal, cerebrovascular and cardiovascular diseases [2,3]. This
raises questions regarding the role of the renal transport protein OATP4C1 for the transport
of both substances across the basolateral membrane of proximal tubule cells. As identified by
Genome Wide Association Studies (GWAS), the major enzyme for endogenous L-homoargi-
nine synthesis seems to be the L-arginine:glycine amidinotransferase (AGAT; also known as
GAMT = Guanidinoacetate N-methyltransferase [5,6]), which is highly expressed in brain,
liver and kidney [18]. Therefore, based on our data, intracellularly synthesized L-homoargi-
nine can be exported out of proximal tubule cells by OATP4C1 whereas extracellularly located
ADMA can be taken up from blood into proximal tubule cells by OATP4C1. Intracellularly,
ADMA is metabolized by the enzyme dimethylarginine dimethylaminohydrolase 1 [DDAH1
[19]], which is expressed in human proximal tubule cells and therefore preventing ADMA
from being re-exported into the systemic circulation by OATP4C1. This hypothesis is sup-
ported by the fact that several studies have observed a moderate decline in L-homoarginine
plasma concentrations with advancing age [20], which can be, at least in part, be explained by
reduced kidney function [2]. Normal L-homoarginine serum concentrations are around
2.6 μM [21], thus, 3–4 times higher compared to ADMA concentrations [21]. During renal
impairment, ADMA concentrations can increase up to 8 μM [22], possibly inhibiting
OATP4C1-mediated L-homoarginine secretion at high concentrations, as demonstrated in
Fig 4. Determination of kinetic constants (Km values) for OATP4C1-mediated net uptake of ADMA (A), L-
arginine (B) and L-homoarginine (C) obtained from experiments with HEK-OATP4C1 and HEK-VC cells.
Presented are net uptake values at indicated substrate concentrations. Data are expressed as means ± SEM. All
experiments were performed on two separate days with n = 2 x 2 each (n = 8).
https://doi.org/10.1371/journal.pone.0213747.g004
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Fig 5. Concentration-dependent inhibition of OATP4C1-mediated L-homoarginine (2 μM) net uptake by uremic toxins ADMA (A) and
SDMA (B). The calculated net uptake values were used to determine IC50 values. Data are expressed as means ± SEM. Experiments were
performed on two separate days with n = 3 (n = 6). �P< 0.05; ���P< 0.0001; one-way ANOVA Dunnett‘s multiple comparison test.
https://doi.org/10.1371/journal.pone.0213747.g005
OATP4C1-mediated transport of ADMA and L-homoarginine
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vitro for the inhibition of digoxin efflux by extracellularly added cyclosporine A and L-homo-
arginine (S1B and S2A Figs).
Furthermore, the findings presented in this manuscript are in line with the observations in
a transgenic rat model overexpressing human OATP4C1 [13], which demonstrated that the
overexpression of human OATP4C1 decreased plasma concentrations of ADMA accompanied
by reduced hypertension, cardiomegaly and inflammation. OATP4C1-mediated uptake of
L-homoarginine could be inhibited by the uremic toxins ADMA and SDMA, but not by other
known uremic toxins, suggesting that more uptake transporters are involved in the renal
secretion of this diverse group of endogenously synthesized metabolites [23]. Candidates
for these transporters include members of the SLC22 family, especially OAT1 (gene symbol
SLC22A6) and OAT3 (SLC22A8). Both transporters are expressed in renal proximal tubule
cells and are capable of transporting several uremic toxins such as indoxyl sulfate, hippurate
and indolacetate [24]. So far, ADMA has been identified as substrate for CAT1 and CAT2
(SLC7 family), for the SLC22 family member OCT2 and the SLC47 member MATE1 [14],
whereas L-homoarginine could be characterized as substrate for the SLC7 family members
CAT1, CAT2A and CAT2B [25]. Furthermore, other transporters of the SLC superfamily
may be involved in the transport of arginine and its derivatives or of uremic toxins into
proximal tubule cells.
During characterization of the stably-transfected cell lines we observed that previously pub-
lished substrates of OATP4C1 [e.g. digoxin [26]] could not be confirmed as uptake substrates
with our cell systems. In contrast, under our standardized uptake conditions adapted from
studies investigating other OATP family members [14,17], we detected a significantly reduced
accumulation of digoxin in HEK-OATP4C1 cells compared with vector-transfected HEK-VC
cells (S1A Fig) suggesting an OATP4C1-mediated export of digoxin. Digoxin has a relatively
high passive diffusion [1.25 μl/min-1 x mg protein-1 [27]] and the OATP4C1-mediated export
out of HEK-OATP4C1 cells after digoxin entering the cells by passive diffusion may result in
the reduced intracellular accumulation compared to HEK-VC cells. Interestingly, this trans-
port can be inhibited by extracellularly added cyclosporine A and L-homoarginine (S1B and
S2A Figs), whereas the uptake of L-homoarginine was also reduced when digoxin is added
extracellularly (S2B Fig), possibly by trans-inhibiting OATP4C1-mediated L-homoarginine
uptake. These results are in line with a study by He and coworkers [28], in which the authors
investigated the interaction between digoxin and bupropion and found that bupropion
increased the renal clearance of digoxin by 80%. The authors suggest that this was due to the
inhibition of digoxin transport during reabsorption, possibly by inhibiting the OATP4C1-me-
diated transport back into blood.
Taken together, we established stably-transfected HEK cells recombinantly overexpressing
the human renal transport protein OATP4C1 and characterized the uremic toxin ADMA as
well as structurally related L-arginine and the protective factor L-homoarginine as substrates.
Furthermore, we could demonstrate that this transporter can act bidirectionally suggesting a
dual protective role of this transport protein. While L-homoarginine could be exported by
OATP4C1 after being synthesized in proximal tubule cells, the OATP4C1-mediated uptake of
ADMA might be a crucial step before intracellular ADMA degradation and subsequent renal
excretion.
Fig 6. Analysis of a possible interaction of uremic toxins with OATP4C1-mediated L-homoarginine net uptake.
All toxins were added in a concentration of 50 μM. Black bars represent the uptake with added uremic toxin (+ 50 μM
uremic toxin) and white bars represent uptake without added putative inhibitor (without), determined under the same
experimental conditions. Data are expressed as means ± SEM. All experiments were performed in two experiments
with n = 2 (n = 4).
https://doi.org/10.1371/journal.pone.0213747.g006
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Fig 7. Investigation of OATP4C1-mediated export of ADMA, L-arginine and L-homoarginine. After preloading the cells with the respective
compound (300 μM), the substrate concentration was measured in the cell lysate (A) and in the supernatant (B) of HEK-OATP4C1 cells (squares)
and HEK-VC cells (circles). The radioactivity in the cells initially after preloading was set to 100% and the values are given related to this
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concentration. Data are expressed as means ± SEM. Experiments were performed on two separate days with at least n = 3 (n� 6). ��P< 0.01;
���P< 0.001.
https://doi.org/10.1371/journal.pone.0213747.g007
Fig 8. Temperature dependency of OATP4C1-mediated L-homoarginine efflux after preloading the cells. After
preloading the cells, the substrate concentration was measured in the cell lysate (A) and in the supernatant (B) of
HEK-OATP4C1 cells (black bars) and HEK-VC cells (white bars) with an incubation temperature of 37 ºC and 4 ºC.
The radioactivity in the cells directly after preloading was set to 100% and the other values are given relative to this
concentration. The studies were performed in two experiments with n = 2 (n = 4). ##P< 0.01 37 ºC HEK-VC versus
4 ºC HEK-VC; ###P< 0.001 37 ºC HEK-VC versus 4 ºC HEK-VC; ��P< 0.01 37 ºC HEK-OATP4C1 versus 37 ºC
HEK-VC; ���P< 0.001 37 ºC HEK-OATP4C1 versus 37 ºC HEK-VC; +++P< 0.001 37 ºC HEK-OATP4C1 versus 4 ºC
HEK-OATP4C1; one-way ANOVA with Bonferroni‘s multiple comparison test.
https://doi.org/10.1371/journal.pone.0213747.g008
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Supporting information
S1 Fig. Uptake of digoxin (5 μM) into HEK-OATP4C1 cells (HEK-OATP4C1) and
HEK-VC cells (HEK-VC). (A) Uptake without added cyclosporine A (CsA). (B) Uptake with
extracellularly added cyclosporine A (10 μM). Data are expressed as means ± SEM. Experi-
ments were conducted on two separate days with n = 3 each (n = 6). ���P< 0.001.
(TIF)
S2 Fig. Interaction of Digoxin and L-homoarginine regarding OATP4C1-mediated trans-
port. (A) Net uptake of digoxin (5 μM) with (+ 20 μM L-homoarginine) and without (without)
extracellularly added L-homoarginine (20 μM) demonstrating that L-homoarginine inhibited
OATP4C1-mediated digoxin efflux. (B) Net uptake of L-homoarginine (20 μM) with (+ 5 μM
Digoxin) and without (without) extracellularly added digoxin (5 μM). Data are expressed as
means ± SEM. Experiments were conducted on two separate days with n = 3 each (n = 6)
�P < 0.05; ���P < 0.001.
(TIF)
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